Relationship between CREPT expression and prognosis in renal cell carcinoma

doi:10.3969/j.issn.1006-7795.2020.04.010

Abstract

Abstract: Objective To explore the expression levels of cell-cycle-related and expression-elevated protein in tumor (CREPT) in renal cell carcinoma (RCC) and its association with cancer prognosis and patient survival. Methods A total of 90 patients who were diagnosed with RCC from 2014 to 2016 in our hospital were enrolled. Immunohistochemistry (IHC) was applied to assess CREPT expression level in RCC and adjacent normal renal tissue. The clinicopathologic features (TNM stage, Fuhrman grade) and CREPT expression level were analyzed. Furthermore, prognostic significance of CREPT was evaluated with Kaplan-Meier survival analysis. Results The expression of CREPT was high in 46.7% (42/90) of the cancer tissues, but low in all the adjacent normal tissues. The difference between groups was statistically significant (P<0.05). The degree of CREPT expression was significantly associated with TNM stage (P=0.001) and Fuhrman grade (P<0.001). However, no significant relationship between CREPT and gender (P=0.149), age (P=0.605), tumor size (P=0.673) and histological type (P=0.756) were identified. Totally 85 patients had completed follow-up until December 2018. The Kaplan-Meier analysis showed that patients with higher expression level of CREPT had significantly worse overall survival (OS) (P<0.05) and disease-free survival (DFS) (P<0.05). Conclusions CREPT was highly expressed in RCC. The expression level was positively associated with the degree of malignancy, clinical stage, and cancer prognosis.

Key words: renal cell carcinoma, cell-cycle-related and expression-elevated protein in tumor(CREPT), prognosis

CLC Number:

R737.11

Liu Jun, Cao Qingfei, Ye Xiongjun, Chen Weinan, Zhao Haiyue, Tong Ming, Wang Yinyin, Huang Xiaobo, Chang Zhijie. Relationship between CREPT expression and prognosis in renal cell carcinoma[J]. Journal of Capital Medical University, 2020, 41(4): 552-557.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.04.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I4/552

References 17

[1]	Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma:mechanisms and management strategies[J]. Mol Cancer Ther, 2018,17(7):1355-1364.
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[3]	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju T F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2018,4(11):1553-1568.
[4]	Choueiri T K, Motzer R J. Systemic therapy for metastatic renal-cell carcinoma[J]. N Engl J Med,2017,376(4):354-366.
[5]	Buchler T, Poprach A, Bortlicek Z, et al. Outcomes of patients with long-term treatment response to vascular endothelial growth factor-targeted therapy for metastatic renal cell cancer[J]. Clin Genitourin Cancer, 2017,15(6):e1047-e1053.
[6]	Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes[J]. Cancer Cell, 2012, 21(1):92-104.
[7]	Sun M, Si G, Sun H S, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway[J]. Biochem Biophys Res Commun, 2018,496(4):1183-1190.
[8]	Sinn B V, von Minckwitz G, Denkert C, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer[J]. Ann Oncol, 2013,24(9):2316-2324.
[9]	Kim J K, Diehl J A. Nuclear cyclin D1:an oncogenic driver in human cancer[J]. J Cell Physiol, 2009, 220(2):292-296.
[10]	Massagué J. G1 cell-cycle control and cancer[J]. Nature, 2004, 432(7015):298-306.
[11]	Karim S, Al-Maghrabi J A, Farsi H M, et al. Cyclin D1 as a therapeutic target of renal cell carcinoma-a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia[J]. BMC Cancer, 2016,16(Suppl 2):741.
[12]	黄子成,陈清,翁晓源,等.Pin1与CyclinD1在胃肠间质瘤中的表达及临床意义[J].中国医科大学学报,2017,46(6):495-500.
[13]	Mei K R, Jin Z, Ren F L, et al. Structural basis for the recognition of RNA polymerase II C-terminal domain by CREPT and p15RS[J]. Sci China Life Sci, 2014, 57(1):97-106.
[14]	Zhang Y, Wang S, Kang W, et al. CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation[J]. Oncogene, 2018,37(26):3485-3500.
[15]	Li W, Zheng G, Xia J, et al. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer[J]. Cancer Sci, 2018,109(4):1012-1023.
[16]	She Y, Liang J, Chen L, et al. CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma[J]. Int J Clin Exp Pathol,2014,7(10):6596-6605.
[17]	Zhang Y, Liu C, Duan X, et al. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the β-catenin·TCF4 transcriptional activity in response to Wnt signaling[J]. J Biol Chem,2014,289(33):22589-22599.